stoxline Quote Chart Rank Option Currency Glossary
Biora Therapeutics, Inc. (PROG)
0.8845  -0.032 (-3.47%)    05-09 00:00
Open: 0.9005
High: 0.92
Volume: 2,779,613
Pre. Close: 0.9163
Low: 0.84
Market Cap: 8(M)
Technical analysis
2022-11-18 4:23:53 PM
Short term     
Mid term     
Targets 6-month :  1.07 1-year :  1.25
Resists First :  0.92 Second :  1.07
Pivot price 0.88
Supports First :  0.87 Second :  0.83
MAs MA(5) :  0.88 MA(20) :  0.88
MA(100) :  0.88 MA(250) :  1.21
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  55.6 D(3) :  55.6
RSI RSI(14): 57.6
52-week High :  3.88 Low :  0.56
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ PROG ] has closed Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 88 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.92 - 0.93 0.93 - 0.93
Low: 0.83 - 0.83 0.83 - 0.84
Close: 0.88 - 0.89 0.89 - 0.89
Company Description

Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. The company develops targeted oral delivery of biotherapeutics, including PGN-600, an orally delivered liquid formulation of tofacitinib for the treatment of ulcerative colitis; and PGN-001, an orally delivered variant of adalimumab for the treatment of ulcerative colitis. It also develops systemic oral delivery of biotherapeutics, which include PGN-OB, a combination product of a variant of adalimumab and the Oral Biotherapeutics Delivery System (OBDM) for the treatment of inflammatory conditions; and PGN-OB2, a combination product of a GLP-1 receptor agonist and the OBDS for the treatment of Type 2 diabetes. In addition, the company develops Recoverable Sampling System, an ingestible smart capsule designed to autonomously identify locations in the GI tract, collect, and preserve a sample for analysis; and PIL Dx, an ingestible smart capsule designed to sample, measure, and transmit results. It has partnership agreement with Ionis Pharmaceuticals to evaluate the OBDS for delivery of antisense oligonucleotides. The company was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California.

Headline News

Mon, 13 May 2024
Biora Therapeutics (BIOR) to Release Quarterly Earnings on Wednesday - Defense World

Mon, 11 Mar 2024
Biora Therapeutics Further Reduces Net Debt and Monetizes Legacy Asset - GlobeNewswire

Tue, 16 Jan 2024
Biora Therapeutics Provides Outlook for 2024 - GlobeNewswire

Tue, 19 Dec 2023
Biora Therapeutics Announces New Patent for its NaviCap™ Targeted Oral Delivery Platform - Yahoo Finance

Fri, 30 Dec 2022
Biora Therapeutics Announces Reverse Stock Split - Yahoo Finance

Tue, 24 May 2022
BIOR Stock Price and Chart — NASDAQ:BIOR — TradingView - TradingView

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 164 (M)
Held by Insiders 1.3945e+008 (%)
Held by Institutions 9.1 (%)
Shares Short 16,790 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.164e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -9 %
Return on Assets (ttm) 449.6 %
Return on Equity (ttm) -56 %
Qtrly Rev. Growth 1.25e+006 %
Gross Profit (p.s.) -0.12
Sales Per Share 0.45
EBITDA (p.s.) -1.26
Qtrly Earnings Growth -3.5 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -167 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 1.92
Price to Cash Flow -0
Stock Dividends
Dividend 0
Forward Dividend 2.065e+007
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android